SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

$BROKE.X is trending due to its recent listing on Bifinance, sparking excitement about increased liquidity and exposure. The community emphasizes the token's survival in the meme coin space, touting its active development and upcoming airdrop. Investors are discussing its potential within the Solana ecosystem, viewing it as an underdog with significant upside.

bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.

BioAffinity Technologies Inc

BioAffinity Technologies ($BIAF) is trending due to news of a China patent award for their noninvasive lung cancer diagnostic, CyPath Lung. While the stock saw an initial surge, community members are actively discussing potential manipulation and resistance levels, with some suggesting the news warrants a significantly higher valuation. The company's low float and potential for further advancements in early cancer detection are also key talking points.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), Global Services (BGS), and Boeing Capital (BCC). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The Boeing Capital segment seeks to ensure that Boeing customers have the financing they need to buy and take delivery of their Boeing product and manages overall financing exposure. The company was founded by William Edward Boeing on July 15, 1916 and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is trending as the FAA is expected to ease restrictions on the 737 MAX production, potentially boosting production rates, while Turkish Airlines may be ordering more Boeing planes after discussions with President Trump. Community members are weighing in on potential price movements, with some anticipating a short squeeze, and discussing the impact of the ongoing strike and new orders on the stock's performance. There is also discussion around a new partnership with Palantir.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costco is trending as investors anticipate the upcoming earnings report, with focus on membership growth and potential tariff impacts. The community is actively discussing whether the company can maintain its growth trajectory amidst rising costs and a high valuation. Technical analysis suggests a bearish pattern, while others point to Costco's defensive strength and consistent customer traffic.

BTQ Technologies Corp. engages in the business of post-quantum encryption. It focuses on applications to the blockchain industry. Its products include PQScale, Keelug, Kenting, Preon, QPoW, and QByte. The company was founded by Nicolas Roussy Newton on March 26, 2021 and is headquartered in Vancouver, Canada.

BTQ Technologies Corp

BTQ Technologies is trending as investors discuss its recent uplisting to the Nasdaq under the new ticker BTQ, a move that is expected to increase exposure and attract institutional investors. The community is weighing the potential for a squeeze given the stock's short interest, while also debating the impact of a possible future dilution. Some investors believe the company is undervalued and poised for significant growth in the quantum computing sector.

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

CRNX is trending following FDA approval of PALSONIFY for acromegaly treatment, though some community members are surprised the stock isn't up more. Despite the positive news, some traders anticipate a selloff due to institutional ownership and short positions, while others are optimistic about a potential short squeeze and future growth.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining is trending amid discussions around a recently announced offering and its potential impact on the stock, with the community debating the implications of the offering's structure and the company's overall financial strategy. Despite some bearish sentiment related to potential dilution, many investors express confidence in Cipher's long-term prospects, particularly its expansion into high-performance computing and a new deal supported by Google. Bullish investors view the offering as a strategic move to fuel growth and capitalize on opportunities in the AI data center space.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

GRRR is trending due to community excitement around a recently announced $1.4 billion contract, with investors citing the potential for significant revenue and a belief that the company is currently undervalued. The community is actively discussing the legitimacy of the contract and awaiting further details from the company to confirm its impact. Some are frustrated by the lack of a corresponding rise in stock price, while others remain optimistic about the long-term potential.

Eason Technology Ltd. engages in the provision of loan facilities to micro, small and medium size enterprises, and sole proprietors. It also offers microfinance lending services. The company was founded by Qi Ming Xu and Kang Kai Zeng on June 24, 2010 and is headquartered in Wuhan, China.

Eason Technology Ltd. - ADR

Eason Technology Ltd ADR

DXF is trending as traders discuss its potential for a short squeeze and compare it to other low-float stocks experiencing significant gains. Community members are noting the stock's compliance news and speculating on upcoming announcements, while highlighting its history of large runs. Some traders point to the small float and potential for volatility, with a few anticipating a substantial price increase.

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

AQST is trending following a recent appearance on Mad Money, where the CEO discussed the potential of their oral allergy film, Anaphylm. Community members are actively discussing the company's prospects, comparing it to competitors, and debating exit strategies as the stock experiences increased visibility. Some investors believe the company is undervalued and are holding for double-digit gains, while others are wary of potential pullbacks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts Predict a 106.48% Upside in Enliven Therapeutics, Inc. (ELVN): Here's  What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 106.5% in Enliven Therapeutics, Inc. (ELVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Enliven Therapeutics, Inc. (ELVN) Upgraded to Buy: Here's What You Should Know

Enliven Therapeutics, Inc. (ELVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

How Much Upside is Left in Enliven Therapeutics, Inc. (ELVN)? Wall Street Analysts Think 102.41%

The consensus price target hints at a 102.4% upside potential for Enliven Therapeutics, Inc. (ELVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Can Enliven Therapeutics, Inc. (ELVN) Climb 75.66% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 75.7% upside potential for Enliven Therapeutics, Inc. (ELVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Short sellers pulled back from Enliven Therapeutics last week, with Ortex data, compiled by The Fly,&nbsp; showing a sharp decline in short interest from 25.7% to 18.4% — the lowest since April 2023.&nbsp;The unwind coincided with a spike in trading volume, triggered by updated Phase 1 results for the company’s chronic myeloid leukemia (CML) candidate ELVN-001 and a bullish initiation from Goldman Sachs.Enliven Therapeutics shares closed at $21.3 on Friday, down 1.3% on the day.Ortex also reported that days to cover, a key metric representing the average number of days it would take shorts to cover their positions at current volume, dropped to 6.9 from 7.8, a nine-month low.&nbsp;The estimated short interest had ranged between 24% and 29% since October 2023.The catalyst was the company’s presentation at the European Hematology Association (EHA) Congress in Milan.&nbsp;Updated data from the ongoing Phase 1 ENABLE trial showed that 25 of 53 evaluable patients without the T315I mutation,&nbsp;or nearly 47%, achieved or maintained major molecular response (MMR) by week 24.&nbsp;The patients in the study were heavily pretreated, with 67% having received three or more prior TKIs.Enliven said ELVN-001 remained well-tolerated across all doses.&nbsp;The drug showed no signs of enhanced cardiovascular risk or arterial occlusive events, with just 3.4% of patients requiring dose reductions due to adverse events and 4.6% discontinuing due to side effects.&nbsp;The drug’s pharmacokinetics support once-daily oral dosing without fasting restrictions and minimal drug-drug interaction, which is a key benefit given&nbsp;that the average CML patient takes about five medications.Additionally, Goldman Sachs initiated coverage on Enliven Therapeutics with a ‘Buy’ rating and a $37 price target, citing positive Phase 1 data for ELVN-001 and plans to start a Phase 3 trial in 2026.&nbsp;The firm said the drug remains well-tolerated, with no added cardiovascular risk, and highlighted its once-daily dosing potential and minimal drug interaction profile.On Stocktwits, retail sentiment was ‘neutral’ amid ‘high’ message volume.The stock has declined 10.9% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Enliven Short Interest Falls To 14-Month Low After Leukemia Trial Data, Goldman Initiates With ‘Buy’

Ortex data shows short interest in Enliven Therapeutics had hovered between 24% and 29% since October 2023.

Equity

Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference PR Newswire BOULDER, Colo., Feb...

Mizuho refreshes its US top picks list for January

Investing.com --  Mizuho  (NYSE:MFG) has updated its US Top Picks list for January, adding Chewy (NYSE:CHWY), GE Vernova (NYSE:GEV), Enliven Therapeutics Inc (NASDAQ:ELVN), Quest Diagnostics (NYSE:DGX), DuPont de Nemours (NYSE:DD), and Salesforce (NYSE:CRM). These selections reflect Mizuho’s highest-conviction ideas driven by catalysts expected to play out over the next 12 months.

Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update

Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update PR Newswire...

Enliven Therapeutics to Present at the Jefferies London Healthcare Conference

Enliven Therapeutics to Present at the Jefferies London Healthcare Conference Enliven Therapeutics to Present at the Jefferies London Healthcare Conference PR Newswire BOULDER, Colo., Nov. 7, 2024...

FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket

FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket PR Newswire VANCOUVER, BC, Oct. 4, 2024 USA News Group...

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002. The company was founded by Samuel S. Kintz, Joseph P. Lyssikatos, and Anish Patel on June 1, 2019 and is headquartered in Boulder, CO.

Enliven Therapeutics Inc

$5,000

$6,000

$7,000

$8,000

What price will Ethereum hit in 2025? 
 
*Powered by Polymarket

Current Price	$18.76
Prev Close	$18.57
Open	$18.79
Dividend Yield	0.00%
50-Day Moving Average	$19.92
Beta	1.23
Avg. Volume	427,294.33
PE Ratio	-9.28

52-Week High	$30.03
52-Week Low	$13.30
Market Capitalization	$1.1B
EPS (Annual)	-$1.89
Price to Book	2.25
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

ELVN
Enliven Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ELVN News

ELVN Enliven Therapeutics Inc